World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
21767
World Ranking
17188
National Ranking
8616

Research.com Recognitions

  • 2017 - Fellow of the American Association for the Advancement of Science (AAAS)
  • 2017 - Fellow of the American Academy of Arts and Sciences
  • 1998 - Member of the National Academy of Medicine (NAM)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Alan M. Garber is affiliated with Baylor College of Medicine in the United States. Their research spans several intersecting fields, incorporating elements of mathematics, medicine, and economics, econometrics, and finance.

Their work engages multiple subfields including modeling and simulation, epidemiology, and economics and econometrics. This multidisciplinary approach informs their analysis and research outputs.

Notable areas of study that have been covered in their research include:

  • COVID-19 epidemiological studies
  • Influenza Virus Research Studies
  • COVID-19 Pandemic Impacts

One recent paper authored by Alan M. Garber is titled "Learning From Excess Pandemic Deaths," published in 2021 in the journal JAMA. This paper has garnered citations indicating engagement from the research community.

The researcher appears predominantly in the journal JAMA as a publication venue, with documented contributions there.

Alan M. Garber has been recognized with several professional distinctions, including:

  • Fellow of the American Association for the Advancement of Science (AAAS), awarded in 2017
  • Fellow of the American Academy of Arts and Sciences, awarded in 2017
  • Member of the National Academy of Medicine (NAM), since 1998
  • Member of the Association of American Physicians

This list of awards reflects affiliations with prominent scientific communities and organizations.

Best Publications

  • Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

    Alan Garber;Robert Henry;Robert Ratner;Pedro A Garcia-Hernandez

  • Economic Foundations of Cost-Effectiveness Analysis

    Alan M. Garber;Alan M. Garber;Alan M. Garber;Charles E. Phelps;Charles E. Phelps

  • Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.

    Michael K. Gould;Anne D. Dembitzer;Ramona L. Doyle;Trevor J. Hastie

  • Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

    Philip Raskin;Elsie Allen;Priscilla Hollander;Andrew Lewin

  • American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan

    Yehuda Handelsman;Jeffrey Mechanick;Lawrence Blonde;George Grunberger

  • Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

    James V. Freeman;Ruo P. Zhu;Douglas K. Owens;Alan M. Garber

  • Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly

    Hau Liu;Dena M. Bravata;Ingram Olkin;Smita Nayak

  • One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel‐group, open‐label trial

    R. Pratley;M. Nauck;T. Bailey;E. Montanya

  • Cost-Effectiveness of Alternative Test Strategies for the Diagnosis of Coronary Artery Disease

    Alan M. Garber;Neil A. Solomon

  • Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis

    Michael K. Gould;Anne D. Dembitzer;Gillian D. Sanders;Alan M. Garber

  • Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging

    Sylvia K. Plevritis;Allison W. Kurian;Bronislava M. Sigal;Bruce L. Daniel

  • Population Strategies to Decrease Sodium Intake and the Burden of Cardiovascular Disease: A Cost-Effectiveness Analysis

    Crystal M. Smith-Spangler;Jessie L. Juusola;Eva A. Enns;Douglas K. Owens

  • Does comparative-effectiveness research threaten personalized medicine?

    Alan M Garber;Sean R. Tunis

  • Population Strategies to Decrease Sodium Intake and the Burden of Cardiovascular Disease

    Crystal M. Smith-Spangler;Jessie L. Juusola;Eva A. Enns;Douglas K. Owens

  • Is American Health Care Uniquely Inefficient

    Alan M. Garber;Jonathan Skinner

  • Trends in Inpatient Treatment Intensity among Medicare Beneficiaries at the End of Life

    Amber E. Barnato;Mark B. Mcclellan;Christopher R. Kagay;Alan M. Garber;Alan M. Garber

  • Liraglutide, a once‐daily human glucagon‐like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

    A. Garber;R. R. Henry;R. R. Henry;R. Ratner;P. Hale

  • AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE 2014 ADVANCED FRAMEWORK FOR A NEW DIAGNOSIS OF OBESITY AS A CHRONIC DISEASE

    W. Garvey;Alan Garber;Jeffrey Mechanick;George Bray

  • Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis

    Michael K. Gould;Anne D. Dembitzer;Ramona L. Doyle;Trevor J. Hastie

  • Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: Lifestyle and Medical Management of Risk Factors

    Scott M. Grundy;Alan Garber;Ronald Goldberg;Stephen Havas

Frequent Co-Authors

Joseph P. Newhouse
Joseph P. Newhouse Harvard University
Jay Bhattacharya
Jay Bhattacharya Stanford University
Mark A. Hlatky
Mark A. Hlatky Stanford University
Mark McClellan
Mark McClellan Duke University
Victor R. Fuchs
Victor R. Fuchs Stanford University
David M. Cutler
David M. Cutler Harvard University
Dana P. Goldman
Dana P. Goldman University of Southern California
Paul A. Heidenreich
Paul A. Heidenreich Stanford University
Charles E. Phelps
Charles E. Phelps University of Rochester
Rong Xu
Rong Xu Case Western Reserve University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA can open the door to many related degrees and career options, especially for those interested in other impactful roles in healthcare. For those considering leadership, a mha degree cost is an important factor to evaluate, as it can influence your return on investment and career trajectory.

Advanced practice nurses seeking to maximize their clinical expertise often look into the cheapest dnp program to pursue their Doctor of Nursing Practice, balancing quality education with affordability. Meanwhile, prospective pharmacists should research the cheapest online pharmacy school to find credible, cost-effective pathways for earning their PharmD.

Finally, with the growing demand for data-driven healthcare, a him bachelor's degree online offers a flexible way to enter the expanding field of health information management. Comparing programs and costs across these options is crucial for making informed decisions about your healthcare career journey.

Best Scientists Citing Alan M. Garber

Trending Scientists

Recently Published Articles